Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VEGF receptors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: VEGF receptors. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000848-26 Sponsor Protocol Number: BMF-AFLI-2013-01 Start Date*: 2013-07-04
    Sponsor Name:Barcelona Macula Foundation
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ...
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001180-11 Sponsor Protocol Number: ML20514 Start Date*: 2009-03-16
    Sponsor Name:Roche Pharma AG
    Full Title: An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated...
    Medical condition: previously untreated metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001016-51 Sponsor Protocol Number: 05-UTROGEL-01 Start Date*: 2006-02-28
    Sponsor Name:Karolinska Hospital
    Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study
    Medical condition: Menopausal symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001750-42 Sponsor Protocol Number: CA209-214 Start Date*: 2014-11-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
    Medical condition: Advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013410-26 Sponsor Protocol Number: ML22229 Start Date*: 2010-02-09
    Sponsor Name:ROCHE SAS
    Full Title: An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab accordin...
    Medical condition: early stage HER2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004076-21 Sponsor Protocol Number: TTD-16-03 Start Date*: 2017-05-30
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed ...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005219-16 Sponsor Protocol Number: GE-135-003 Start Date*: 2010-12-06
    Sponsor Name:GE Healthcare Ltd
    Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging
    Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004391-39 Sponsor Protocol Number: CTKI258A2107 Start Date*: 2008-04-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)
    Medical condition: advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000759-20 Sponsor Protocol Number: CA209-9ER Start Date*: 2017-08-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
    Medical condition: Advanced or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) FR (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001777-19 Sponsor Protocol Number: HOVON 81 AML Start Date*: 2006-12-07
    Sponsor Name:HOVON foundation
    Full Title: A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
    Medical condition: Acute myeloid leukaemia (AML), AML FAB M0-M2 or M4-M7; diagnosis with refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-T) with an IP...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000300-10 Sponsor Protocol Number: IDI-AFLI-2013-01 Start Date*: 2014-04-23
    Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL)
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study.
    Medical condition: Retinal angiomatous proliferation lesions (RAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004078-25 Sponsor Protocol Number: VEG105192 Start Date*: 2006-03-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or...
    Medical condition: Locally Advanced and/or metastatic renal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050076 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SK (Completed) LT (Completed) EE (Completed) AT (Completed) CZ (Completed) IT (Completed) GR (Prematurely Ended) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-000662-23 Sponsor Protocol Number: BO21015 Start Date*: 2008-10-28
    Sponsor Name:F. Hoffmann La-Roche Ltd
    Full Title: A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, w...
    Medical condition: Locally advanced, metastatic or recurrent Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Completed) BE (Completed) DE (Completed) DK (Completed) CZ (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002063-14 Sponsor Protocol Number: GEMCAD-1402 Start Date*: 2014-10-23
    Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo)
    Full Title: Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial
    Medical condition: Patients with high risk locally advanced rectal carcinoma (defined by Magnetic Resonance Imaging [MRI]), who are candidates for multimodality treatment.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-009154-25 Sponsor Protocol Number: omalizumab/2009/01 Start Date*: 2009-07-07
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St.Thomas' NHS Foundation Trust
    Full Title: The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000783-16 Sponsor Protocol Number: ML21531 Start Date*: 2008-06-18
    Sponsor Name:ROCHE SAS
    Full Title: Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast ca...
    Medical condition: Primary inflammatory HER2+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004691-37 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:St Vincents University Hospital
    Full Title: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients.
    Medical condition: Psoriasis and Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002307-26 Sponsor Protocol Number: 0216-ASG Start Date*: 2016-09-15
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma
    Medical condition: subjects with previously untreated (1st line) or pretreated (2nd line), intermediate or high risk, advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038400 Renal carcinoma stage IV LLT
    20.0 100000004864 10038399 Renal carcinoma stage III LLT
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:52:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA